COMP <GO>
CGEN vs UNH // OPERATING MARGIN
Compugen Ltd. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CGEN 7
— UNH 4
▲ OPERATING MARGIN LEADER: CGEN
LAST: $1.98 (-2.94%) • MKT CAP: $193.0M
operating-margins
43.10%
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
operating-margins
4.82%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGEN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 88.57% | -1.27 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 11.47% | +73.53 | CGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.2x | 16.4x | -13.25 | CGEN | /valuation <GO> |
| Free Cash Flow Yield | 16.24% | 6.48% | +9.76 | CGEN | /fcf-yield <GO> |
| Operating Margin ACTIVE | 43.10% | 4.82% | +38.28 | CGEN | /operating-margins <GO> |
| Net Profit Margin | 48.60% | 3.14% | +45.46 | CGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 161.10% | 6.46% | +154.64 | CGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.12 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 59.2 | -18.06 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.6x | 17.7x | -13.14 | CGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $193.0M | $368.83B | -$368.64B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGEN REV | UNH REV | CGEN GROSS % | UNH GROSS % | CGEN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $72.8M | $447.57B | 87.3% | 88.7% | $31.3M | $16.07B |
| FY 2024 | $27.9M | $400.28B | 71.5% | 88.3% | $49.5M | $20.70B |
| FY 2023 | $33.5M | $371.62B | — | 89.6% | -$35.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEN // BETA —
UNH // BETA 0.33